183 related articles for article (PubMed ID: 31646908)
21. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
22. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
23. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
Fernandez H; Schmidt T; Powell M; Costa AP; Arriagada P; Thaler C
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():91-96. PubMed ID: 27898340
[TBL] [Abstract][Full Text] [Related]
24. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
25. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
26. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
28. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
29. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.
Biglia N; Carinelli S; Maiorana A; D'Alonzo M; Lo Monte G; Marci R
Drug Des Devel Ther; 2014; 8():285-92. PubMed ID: 24591818
[TBL] [Abstract][Full Text] [Related]
30. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
33. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract][Full Text] [Related]
34. Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate.
Chang MC; Latta E
Int J Gynecol Pathol; 2020 Mar; 39(2):146-151. PubMed ID: 30702466
[TBL] [Abstract][Full Text] [Related]
35. Management of symptomatic uterine fibroids with ulipristal acetate: A retrospective, multicentric and nationwide study.
Águas F; Guerreiro F; Ponte C; Gomes C; Martinho M; Vilhena V; Silva D
J Gynecol Obstet Hum Reprod; 2020 Oct; 49(8):101862. PubMed ID: 32652302
[TBL] [Abstract][Full Text] [Related]
36. Acute Liver Failure Associated With Ulipristal Acetate: A Case Report.
Carballo-Folgoso L; Alvarez-Navascués C; Rodriguez M
Am J Gastroenterol; 2020 Sep; 115(9):1542-1544. PubMed ID: 32701736
[No Abstract] [Full Text] [Related]
37. Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Conway F; Morosetti G; Camilli S; Martire FG; Sorrenti G; Piccione E; Zupi E; Exacoustos C
Gynecol Endocrinol; 2019 Mar; 35(3):207-210. PubMed ID: 30382803
[TBL] [Abstract][Full Text] [Related]
38. Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis.
Hong YH; Han SJ; Lee D; Kim SK; Jee BC
J Obstet Gynaecol Res; 2019 Apr; 45(4):865-870. PubMed ID: 30675965
[TBL] [Abstract][Full Text] [Related]
39. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
40. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]